Phaseline

Targets › DNA-PKCS

DNA-PKCS: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2028.

Open in Phaseline: the race on DNA-PKCS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of LeedsAZD5305
DNA-PKcs kinase inhibitor
DNA-PKCSPhase 1Non Small Cell Lung CancerMar 2028

Conditions

Non Small Cell Lung Cancer (1)

Modalities

mixed (1)

Companies

University of Leeds (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.